全文获取类型
收费全文 | 894篇 |
免费 | 31篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 13篇 |
妇产科学 | 12篇 |
基础医学 | 94篇 |
口腔科学 | 5篇 |
临床医学 | 45篇 |
内科学 | 234篇 |
皮肤病学 | 18篇 |
神经病学 | 20篇 |
特种医学 | 16篇 |
外国民族医学 | 1篇 |
外科学 | 214篇 |
综合类 | 20篇 |
预防医学 | 38篇 |
眼科学 | 13篇 |
药学 | 71篇 |
中国医学 | 5篇 |
肿瘤学 | 74篇 |
出版年
2023年 | 13篇 |
2022年 | 16篇 |
2021年 | 48篇 |
2020年 | 24篇 |
2019年 | 16篇 |
2018年 | 33篇 |
2017年 | 17篇 |
2016年 | 21篇 |
2015年 | 20篇 |
2014年 | 30篇 |
2013年 | 37篇 |
2012年 | 58篇 |
2011年 | 59篇 |
2010年 | 41篇 |
2009年 | 36篇 |
2008年 | 64篇 |
2007年 | 57篇 |
2006年 | 62篇 |
2005年 | 57篇 |
2004年 | 40篇 |
2003年 | 43篇 |
2002年 | 38篇 |
2001年 | 10篇 |
2000年 | 9篇 |
1999年 | 9篇 |
1998年 | 3篇 |
1997年 | 7篇 |
1996年 | 2篇 |
1995年 | 6篇 |
1994年 | 2篇 |
1993年 | 7篇 |
1992年 | 4篇 |
1991年 | 2篇 |
1990年 | 4篇 |
1989年 | 2篇 |
1987年 | 2篇 |
1986年 | 4篇 |
1985年 | 3篇 |
1973年 | 2篇 |
1972年 | 3篇 |
1960年 | 2篇 |
1947年 | 1篇 |
1942年 | 1篇 |
1941年 | 1篇 |
1940年 | 1篇 |
1938年 | 1篇 |
1937年 | 1篇 |
1936年 | 1篇 |
1930年 | 2篇 |
1929年 | 1篇 |
排序方式: 共有929条查询结果,搜索用时 15 毫秒
921.
Michael Böhm Javed Butler Marcin Krawczyk Felix Mahfoud Bernhard Haring Gerasimos Filippatos João Pedro Ferreira Stuart J. Pocock Martina Brueckmann Anne Pernille Ofstad Elke Schüler Christoph Wanner Subodh Verma Milton Packer Stefan D. Anker the EMPEROR-Preserved Trial Committees Investigators 《European journal of heart failure》2023,25(8):1375-1383
Aim
The prognostic implication of elevated liver tests in heart failure with preserved ejection fraction (HFpEF) is uncertain. This analysis investigates the association of liver markers with hospitalization for heart failure (HHF) and cardiovascular death (CVD), and the treatment effect of empagliflozin across the range of liver marker levels.Methods and results
The double-blind, placebo-controlled EMPEROR-Preserved (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure with Preserved Ejection Fraction) enrolled 5988 patients with HFpEF (ejection fraction >40%). Patients in New York Heart Association class II–IV and elevated N-terminal pro-B-type natriuretic peptide were randomized to receive empagliflozin 10 mg daily or placebo in addition to usual therapy. Patients with significant liver disease were excluded. The primary endpoint was time to first adjudicated HHF or CVD. We explored the association of liver function abnormalities with heart failure outcomes in patients on placebo, the effects of empagliflozin on liver tests and the treatment effects of empagliflozin on heart failure outcomes across categories of liver laboratory values. High alkaline phosphatase (p trend < 0.0001), low albumin (p trend < 0.0001) and high bilirubin (p = 0.02) were associated with poorer outcomes for HHF or CVD, while high aspartate aminotransferase was not, and high alanine aminotransferase was associated with better outcomes. Empagliflozin had no significant effects on liver tests compared to placebo except for albumin which was significantly increased. The treatment effect of empagliflozin on outcomes was not modified by liver tests.Conclusion
Abnormalities of liver function tests are associated differently with heart failure outcomes. Salutary effects of empagliflozin on liver tests were not observed although albumin increased. The treatment benefits of empagliflozin were not affected by baseline values of liver parameters. 相似文献922.
923.
924.
Diana Wu Ying Li Yu Bi Trevor M. Lannom Deborah A. Ward Amr Qudeimat Renee M. Madden Akshay Sharma Rebecca Epperly Ewelina Mamcarz Aimee Talleur Swati Naik Subodh Selukar Brandon Triplett Ashok Srinivasan 《Pediatric blood & cancer》2023,70(9):e30517
Calcineurin inhibitors (CNI), cyclosporine and tacrolimus, are commonly used for pharmacologic prophylaxis of graft-versus-host disease after allogeneic hematopoietic cell transplantation (HCT). Unfortunately, their use is associated with significant toxicities. While intolerance to CNI is well defined, there is very little information on how they impact outcomes after HCT in children. Our retrospective study in a cohort of 82 children shows a high intolerance rate of 39% in this population associated with lower event-free survival and a higher transplant-related mortality. 相似文献
925.
926.
927.
Tariq Jamal Siddiqi Stefan D. Anker Gerasimos Filippatos João Pedro Ferreira Stuart J. Pocock Michael Böhm Martina Brueckmann Vijay K. Chopra Tomoko Iwata James Januzzi Ileana L. Piña Piotr Ponikowski Michele Senni Ola Vedin Subodh Verma Yuhui Zhang Faiez Zannad Milton Packer Javed Butler 《European journal of heart failure》2023,25(9):1623-1631
Aims
There are limited data on health status and changes in it over time across major subgroups of patients with heart failure and preserved ejection fraction (HFpEF), including ejection fraction spectrum, age, sex, region, body mass index (BMI), and comorbidities including diabetes, chronic kidney disease (CKD), anaemia, and atrial fibrillation/flutter.Methods and results
In the EMPEROR-Preserved trial, the Kansas City Cardiomyopathy Questionnaire (KCCQ) was assessed at baseline, 12, 32 and 52 weeks. Determinants of baseline KCCQ score and change over time, and the impact of empagliflozin on KCCQ scores were studied in specified subgroups. A Cox model was used to assess the association between 5- and 10-point increase and 5-point decrease in KCCQ score from baseline to week 12 and later outcomes. Among 2979 participants in the placebo arm, mean KCCQ clinical summary score (CSS) was 70.7 (20.8). Older age, female sex, BMI, anaemia, and a history of diabetes, and CKD were associated with worse scores. KCCQ-CSS score improved during follow-up; patients with atrial fibrillation/flutter at enrollment (p trend = 0.014) and CKD (p trend < 0.001) had less improvement. A 5-point increase in KCCQ-CSS at week 12 was associated with lower risk of cardiovascular death or heart failure hospitalization (5%), cardiovascular death (8%), and first heart failure hospitalization (4%) subsequently. A similar trend was seen with KCCQ total symptom score (TSS) and overall summary score (OSS). Empagliflozin improved KCCQ-CSS, -TSS and -OSS scores similarly across subgroups studied except for greater improvement in patients with the highest BMI (p trend = 0.153, 0.08 and 0.078, respectively).Conclusion
Health status in patients with HFpEF is impaired, especially in elderly, women, and those with obesity and comorbidities. Empagliflozin improved health status among all key subgroups studied with a greater effect in obese patients. 相似文献928.